دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Access to cancer medicines in the UK
doi : 10.1016/S1470-2045(23)00109-2
Volume 24, Issue 5, May 2023, Page 415
Metastatic prostate cancer management: 20 years of progress
doi : 10.1016/S1470-2045(23)00167-5
Volume 24, Issue 5, May 2023, Pages 416-417
Fluorescence in prostate cancer surgery
*Daniele Amparore, Francesco Porpiglia
doi : 10.1016/S1470-2045(23)00164-X
Volume 24, Issue 5, May 2023, Pages 417-419
Combination chemo-immunotherapy in advanced oesophageal squamous cell carcinoma
Katrin Marie Sjoquist
doi : 10.1016/S1470-2045(23)00151-1
Volume 24, Issue 5, May 2023, Pages 419-420
Evaluating drug delivery enhancement following ultrasound treatment
Antonios N Pouliopoulos
doi : 10.1016/S1470-2045(23)00149-3
Volume 24, Issue 5, May 2023, Pages 420-422
Craniopharyngiomas and proton beam therapy: worth the expense?
*Ashley Grossman, Michael Kosmin
doi : 10.1016/S1470-2045(23)00162-6
Volume 24, Issue 5, May 2023, Pages 422-423
Belzutifan: enhancing the blockade of angiogenesis in renal cell carcinoma
*Veronica Mollica, Francesco Massari
doi : 10.1016/S1470-2045(23)00123-7
Volume 24, Issue 5, May 2023, Pages 423-425
A major conditions strategy cannot replace a national cancer plan—patient advocates voice their concerns
Roger Wilson, Emma Kinloch, Lydia E Makaroff, Anna Bailey-Bearfield, Richard Stephens, Janette Rawlinson, Kathy Oliver
doi : 10.1016/S1470-2045(23)00145-6
Volume 24, Issue 5, May 2023, Pages 425-427
Strategies for cancer-care resilience during the new COVID-19 wave in China
Liang V Tang, *Yu Hu
doi : 10.1016/S1470-2045(23)00121-3
Volume 24, Issue 5, May 2023, Pages 428-430
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm
Giuseppe Lamberti, Elisa Andrini, Claudio Ricci, Davide Campana
doi : 10.1016/S1470-2045(23)00059-1
Volume 24, Issue 5, May 2023, Page e187
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm
Melik Kagan Aktas, Erman Aytac, IbrahimYildiz, *Leyla Ozer
doi : 10.1016/S1470-2045(23)00098-0
Volume 24, Issue 5, May 2023, Page e188
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm
Thorvardur R Halfdanarson, Travis E Grotz, Hallbera Gudmundsdottir, Sean P Cleary
doi : 10.1016/S1470-2045(23)00122-5
Volume 24, Issue 5, May 2023, Page e189
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm – Authors' reply
Reto M Kaderli, Cédric Nesti, Konstantin Bräutigam, Marcel Zwahlen, Aurel Perren
doi : 10.1016/S1470-2045(23)00114-6
Volume 24, Issue 5, May 2023, Pages e190-e191
Correction to Lancet Oncol 2022; 23: (Abstracts from The Lancet Summit: Cancer care in Asia and Latin America Special Issue): S28
doi : 10.1016/S1470-2045(23)00176-6
Volume 24, Issue 5, May 2023, Page e192
Correction to Lancet Oncol 2022; 23: 1308–20
doi : 10.1016/S1470-2045(23)00177-8
Volume 24, Issue 5, May 2023, Page e192
Correction to Lancet Oncol 2023; 24: 403–14
doi : 10.1016/S1470-2045(23)00178-X
Volume 24, Issue 5, May 2023, Page e192
Carcinogenicity of anthracene, 2-bromopropane, butyl methacrylate, and dimethyl hydrogen phosphite
Russell C Cattley, Hans Kromhout, Meng Sun, Erik J Tokar, Mohamed A-E Abdallah, Alison K Bauer, Kendra R Broadwater, Laura Campo, Emanuela Corsini, Keith A Houck, Gaku Ichihara, Michiharu Matsumoto, Simone Morais, Jaroslav Mráz, Tetsuo Nomiyama, Kristen Ryan, Huizhong Shen, Takeshi Toyoda, Kirsi Vähäkangas, Marianna G Yakubovskaya, Il Je Yu, Nathan L DeBono, Aline de Conti, Fatiha El Ghissassi, Federica Madia, Heidi Mattock, Elisa Pasqual, Eero Suonio, Roland Wedekind, *Lamia Benbrahim-Tallaa, *Mary K Schubauer-Berigan
doi : 10.1016/S1470-2045(23)00141-9
Volume 24, Issue 5, May 2023, Pages 431-432
Challenges to patient access to controlled drugs in the USA
Sharmila Devi
doi : 10.1016/S1470-2045(23)00142-0
Volume 24, Issue 5, May 2023, Page 433
Students and researchers from China barred from working in the UK
Manjulika Das
doi : 10.1016/S1470-2045(23)00143-2
Volume 24, Issue 5, May 2023, Page 434
Biden Administration appeals federal judge ruling on ACA
Manjulika Das
doi : 10.1016/S1470-2045(23)00160-2
Volume 24, Issue 5, May 2023, Page 435
US Government releases National Cancer Plan
Bryant Furlow
doi : 10.1016/S1470-2045(23)00168-7
Volume 24, Issue 5, May 2023, Page 436
UK Government “swap to stop� plan to cut smoking rates
Emma Wilkinson
doi : 10.1016/S1470-2045(23)00169-9
Volume 24, Issue 5, May 2023, Page 437
Sweeping new US EPA air pollution rules
Bryant Furlow
doi : 10.1016/S1470-2045(23)00161-4
Volume 24, Issue 5, May 2023, Page 438
AACR Annual Meeting 2023
Cheryl Reeves
doi : 10.1016/S1470-2045(23)00179-1
Volume 24, Issue 5, May 2023, Pages e193-e194
ASTRO embraces Final Rule by CMS
Manjulika Das
doi : 10.1016/S1470-2045(23)00180-8
Volume 24, Issue 5, May 2023, Page e195
EU cancer drug leaflets contain insufficient information
Elizabeth Gourd
doi : 10.1016/S1470-2045(23)00181-X
Volume 24, Issue 5, May 2023, Page e196
The rise of immuno-oncology in China: a challenge to western dominance?
Mark P Lythgoe, Grant Lewison, Ajay Aggarwal, Chris Booth, Mark Lawler, Dario Trapani, Manju Sengar, Richard Sullivan
doi : 10.1016/S1470-2045(23)00026-8
Volume 24, Issue 5, May 2023, Pages 439-441
The European Cancer Pulse: tracking inequalities in cancer control for citizen benefit
Norbert Couespel, Enea Venegoni, Mark Lawler
doi : 10.1016/S1470-2045(23)00140-7
Volume 24, Issue 5, May 2023, Pages 441-442
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
Gerhardt Attard, Laura Murphy, Noel W Clarke, Ashwin Sachdeva, Craig Jones, Alex Hoyle, William Cross, Robert J Jones, Christopher C Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Clare Gilson, Hannah Rush, Hoda Abdel-Aty, Claire L Amos, Claire Murphy, Simon Chowdhury, Zafar Malik, J Martin Russell, Nazia Parkar, Cheryl Pugh, Carlos Diaz-Montana, Carmel Pezaro, Warren Grant, Helen Saxby, Ian Pedley, Joe M O’Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzouebi, Omi Parikh, Angus Robinson, Amir H Montazeri, James Wylie, Anjali Zarkar, Richard Cathomas, Michael D Brown, Yatin Jain, David P Dearnaley*, Malcolm D Mason*, Duncan Gilbert, Ruth E Langley, Robin Millman, David Matheson, Matthew R Sydes†, Louise C Brown†, Mahesh K B Parmar†, Nicholas D James†, for the STAMPEDE investigators
doi : 10.1016/S1470-2045(23)00148-1
Volume 24, Issue 5, May 2023, Pages 443-456
First-in-patient study of OTL78 for intraoperative fluorescence imaging of prostate-specific membrane antigen-positive prostate cancer: a single-arm, phase 2a, feasibility trial
Judith A Stibbe*, Hilda A de Barros*, Daan G J Linders, Shadhvi S Bhairosingh, Elise M Bekers, Pim J van Leeuwen, Philip S Low, Sumith A Kularatne, Alexander L Vahrmeijer, Jacobus Burggraaf†, Henk G van der Poel
doi : 10.1016/S1470-2045(23)00102-X
Volume 24, Issue 5, May 2023, Pages 457-467
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial
Linda R Mileshkin*, Kathleen N Moore*, Elizabeth H Barnes, Val Gebski, Kailash Narayan, Madeleine T King, Nathan Bradshaw, Yeh Chen Lee, Katrina Diamante, Anthony W Fyles, William Small Jr, David K Gaffney, Pearly Khaw, Susan Brooks, J Spencer Thompson, Warner K Huh, Cara A Mathews, Martin Buck, Aneta Suder, Thomas E Lad, Igor J Barani, Christine H Holschneider, Sylvia Van Dyk, Michael Quinn, Danny Rischin, Bradley J Monk†, Martin R Stockler
doi : 10.1016/S1470-2045(23)00147-X
Volume 24, Issue 5, May 2023, Pages 468-482
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
Jianming Xu, Ken Kato, Eric Raymond, Richard A Hubner, Yongqian Shu, Yueyin Pan, Sook Ryun Park, Lu Ping, Yi Jiang, Jingdong Zhang, Xiaohong Wu, Yuanhu Yao, Lin Shen, Takashi Kojima, Evgeny Gotovkin, Ryu Ishihara, Lucjan Wyrwicz, Eric Van Cutsem, Paula Jimenez-Fonseca, Chen-Yuan Lin, Lei Wang, Jingwen Shi, Liyun Li, Harry H Yoon
doi : 10.1016/S1470-2045(23)00108-0
Volume 24, Issue 5, May 2023, Pages 483-495
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
John H Strickler, Andrea Cercek, Salvatore Siena, Thierry André, Kimmie Ng, Eric Van Cutsem, Christina Wu, Andrew S Paulson, Joleen M Hubbard, Andrew L Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon M Kasi, Heinz-Josef Lenz, Kristen K Ciombor, Elena Elez, David L Bajor, Chiara Cremolini, Federico Sanchez, Michael Stecher, Wentao Feng, Tanios S Bekaii-Saab, on behalf of the MOUNTAINEER investigators
doi : 10.1016/S1470-2045(23)00150-X
Volume 24, Issue 5, May 2023, Pages 496-508
Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial
Adam M Sonabend, Andrew Gould, Christina Amidei, Rachel Ward, Karyn A Schmidt, Daniel Y Zhang, Cristal Gomez, John F Bebawy, Benjamin P Liu, Guillaume Bouchoux, Carole Desseaux, Irene B Helenowski, Rimas V Lukas, Karan Dixit, Priya Kumthekar, VÃctor A Arrieta, Maciej S Lesniak, Alexandre Carpentier, Hui Zhang, Miguel Muzzio, Michael Canney, Roger Stupp
doi : 10.1016/S1470-2045(23)00112-2
Volume 24, Issue 5, May 2023, Pages 509-522
Proton therapy and limited surgery for paediatric and adolescent patients with craniopharyngioma (RT2CR): a single-arm, phase 2 study
Thomas E Merchant, Mary Ellen Hoehn, Raja B Khan, Noah D Sabin, Paul Klimo, Frederick A Boop, Shengjie Wu, Yimei Li, Elizabeth A Burghen, Niki Jurbergs, Eric S Sandler, Philipp R Aldana, Daniel J Indelicato, Heather M Conklin
doi : 10.1016/S1470-2045(23)00146-8
Volume 24, Issue 5, May 2023, Pages 523-534
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
Peter Hillmen, Alexandra Pitchford, Adrian Bloor, Angus Broom, Moya Young, Ben Kennedy, Renata Walewska, Michelle Furtado, Gavin Preston, Jeffrey R Neilson MBChB, Nicholas Pemberton, Gamal Sidra, Nicholas Morley, Kate Cwynarski, Anna Schuh, Francesco Forconi, Nagah Elmusharaf, Shankara Paneesha , Christopher P Fox, Dena R Howard, Anna Hockaday, Julia M Brown, David A Cairns, Sharon Jackson, Natasha Greatorex, Nichola Webster, Jane Shingles, Surita Dalal, Piers E M Patten, David Allsup, Andrew Rawstron, Talha Munir
doi : 10.1016/S1470-2045(23)00144-4
Volume 24, Issue 5, May 2023, Pages 535-552
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
Toni K Choueiri, David F McDermott, Jaime Merchan, Todd M Bauer, Robert Figlin, Elisabeth I Heath, M Dror Michaelson, Edward Arrowsmith, Anishka D’Souza, Song Zhao, Ananya Roy, Rodolfo Perini, Donna Vickery, Scott S Tykodi
doi : 10.1016/S1470-2045(23)00097-9
Volume 24, Issue 5, May 2023, Pages 553-562
Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa
Kadia Petricca, Joyce Kambugu, Jessie Githang’a, William M Macharia, Festus Njuguna, Angela McLigeyo, Mary Nyangasi, Jackson Orem, Aimable Kanyamuhunga, Rehema Laiti, Deogratias Katabalo, Kristin Schroeder, Khama Rogo, Bryan Maguire, Lucy Wambui, Jean N Nkurunziza, Bryan Wong, Joshua Neposlan, Lilian Kilawe, Sumit Gupta, Avram E Denburg
doi : 10.1016/S1470-2045(23)00072-4
Volume 24, Issue 5, May 2023, Pages 563-576
Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice
Limin Liu, Jungyeon Choi, Jammbe Z Musoro, Willi Sauerbrei, Cecilie Delphin Amdal, Ahu Alanya, Yolanda Barbachano, Joseph C Cappelleri, Ragnhild Sørum Falk, Mallorie H Fiero, Antoine Regnault, Jaap C Reijneveld, Rickard Sandin, Doranne Thomassen, Satrajit Roychoudhury, Els Goetghebeur, Saskia le Cessie, on behalf of SISAQOL-IMI Work Package 3
doi : 10.1016/S1470-2045(23)00110-9
Volume 24, Issue 5, May 2023, Pages e197-e206
Defining the road map to a UK national lung cancer screening programme
Emma L O’Dowd*, Richard W Lee*, Ahsan R Akram, Emily C Bartlett, Stephen H Bradley, Kate Brain, Matthew E J Callister, Yan Chen, Anand Devaraj, Sinan R Eccles, John K Field, Jesme Fox, Seamus Grundy, Sam M Janes, Martin Ledson, Melanie MacKean, Anne Mackie, Kieran G McManus, Rachael L Murray, Arjun Nair, Samantha L Quaife, Robert Rintoul, Anne Stevenson, Yvonne Summers, Louise S Wilkinson, Richard Booton, David R Baldwin†, Philip Crosbieâ€
doi : 10.1016/S1470-2045(23)00104-3
Volume 24, Issue 5, May 2023, Pages e207-e218
REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment
Ehsan Ghorani*, Matteo Quartagno*, Fiona Blackhall, Duncan C Gilbert, Mary O’Brien, Christian Ottensmeier, Elena Pizzo, James Spicer, Alex Williams, Philip Badman, Mahesh K B Parmar*, Michael J Seckl* on behalf of the REFINE-Lung Investigators
doi : 10.1016/S1470-2045(23)00095-5
Volume 24, Issue 5, May 2023, Pages e219-e227
Alveolar rhabdomyosarcoma with multiple bone marrow infiltration
Kun Wang, Zhihong Chen, Yanchun Li, Zhiqun Mao
doi : 10.1016/S1470-2045(23)00015-3
Volume 24, Issue 5, May 2023, Page e228
